FinCanna Signs Royalty Agreement with Green Compliance for U.S. Medical Cannabis Compliance Software

HIPAA Compliant Software Targets all 29 U.S. States Which Have Legalized Medical Cannabis and Diversifies the FinCanna Royalty Investment Portfolio


VANCOUVER, British Columbia, Feb. 06, 2018 (GLOBE NEWSWIRE) -- FinCanna Capital Corp. (“FinCanna”) (CSE:CALI), have entered into a royalty agreement with Green Compliance, Inc. (“Green Compliance”). Green Compliance, headquartered in Fort Lauderdale, Florida, offers a state-of-the-art enterprise compliance and point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

Green Compliance has commenced sales in the United States, and its target market is every licensed operating dispensary and cultivator in the states which have passed laws legalizing medical cannabis - currently 29 states and Washington, D.C. Its ezGreen compliance software offers a security and HIPAA compliance strategy for dispensaries operating with valid licenses within their respective states. Most dispensaries use a seed-to-sale solution, and ezGreen has the flexibility to integrate as a plug-in with any existing seed-to-sale software or it can operate as a stand-alone point-of-sale system.

FinCanna CEO, Andriyko Herchak, comments, “We are building a diversified portfolio of royalty investments in companies that have the potential to be the leaders in their respective sectors of the licensed medical cannabis industry. Green Compliance, with its deep-rooted experience in compliance software and medical cannabis industry expertise, is an ideal addition to our royalty portfolio. Green Compliance has already commenced sales, and we expect our royalties to commence in the near future, with a tremendous opportunity for growth across all 29 U.S. states and Washington D.C. which have legalized medical cannabis.“

Green Compliance has an exclusive licensing and support agreement with Automated Healthcare Solutions (“AHCS”) to market and sell ezGreen compliance software. AHCS is a leading point of care tracking and dispensing software solution in the U.S. dedicated to the workers compensation vertical in the pharmaceutical industry, and a proven HIPAA compliant solution. AHCS supports thousands of active physicians that dispense medication onsite and has tracked, monitored, reported, and protected patient information for the past 16 years across thousands of physician practices, while maintaining HIPAA compliance and following Health and Human Services protocols in the United States.  

Together, AHCS and Green Compliance developed ezGreen compliance software to offer similar compliance guidelines, standards, and disciplines at the U.S. state level to the licensed medical cannabis industry as is done in the pharmaceutical industry. The ezGreen compliance software includes a suite of tools including state-by-state compliance, tracking, reporting, point-of-sale dispensing and product verification services. 

HIPAA is one of the most significant medical data handling regulation systems in the United States. It has become the template for establishing regulatory requirements for all other industries in regard to handling sensitive patient information. HIPAA regulations have become more stringent due to the substantial increase in identity theft in recent years.

To ensure enforcement of these regulatory requirements, HIPAA is now in the secondary phase of auditing medical organizations which has resulted in over $75 million in fines to date.  The penalties for noncompliance are based on the level of negligence and can reach $50,000 per violation (or per record), with a maximum penalty of $1.5 million per year for violations of an identical provision. Violations can also carry criminal charges that can result in jail time. Almost 90% of healthcare organizations have experienced a data breach in the past 24 months with 45% of those experiencing five or more breaches in that period of time.

Under the Royalty Agreement, FinCanna will fund US$3 million in tranches by September 15, 2018. In return, FinCanna will receive a perpetual royalty equal to 10% of consolidated gross revenues of Green Compliance, subject to certain buy-back options.

Green Compliance has also partnered with Chameleon Collective, a strategy-based agency that drives marketing, business development, and innovation across the media, retail, and technology sectors.  Chameleon Collective was founded by senior executives, marketers, technologists, entrepreneurs, and change-makers that also have a deep cannabis industry network. Chameleon Collective will help drive marketing, business development and innovation across the media, retail and technology sectors for Green Compliance on a U.S. national level.

FinCanna CEO, Andriyko Herchak, adds, “Partnering with Green Compliance and Chameleon Collective is a very strategic opportunity to increase our presence across the U.S., help fund best-in-class companies and projects, and expand our diversified portfolio of royalty investments. Excelling at compliance solutions and building strong relationships with its customer base and with regulators will be an effective way for Green Compliance to become a trusted provider and open doors for a number of additional growth opportunities.”

About FinCanna Capital Corp.

FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues. FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California. For additional information visit www.fincannacapital.com  and FinCanna’s profile at www.sedar.com.

FinCanna Capital Corp. 
Andriyko Herchak, CEO & Director

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about the market for, and effectiveness of, ezGreen software, the ability of Green Compliance to expand operations and generate sales and revenues, the results of operations of Chameleon Collective, FinCanna’s ability to fund and source future projects, and FinCanna’s ability to earn and realize revenues from its investee companies.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement available at www.SEDAR.com and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made, and the respective companies undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.